CMS: Medicare Program; Calendar Year (CY) 2024 Home Health (HH) Prospective Payment System Rate Update; HH Quality Reporting Program Requirements; HH Value-Based Purchasing Expanded Model Requirements; Home Intravenous Immune Globulin Items and Services; Hospice Informal Dispute Resolution and Special Focus Program Requirements, Certain Requirements for Durable Medical Equipment Prosthetics and Orthotics Supplies; and Provider and Supplier Enrollment Requirements; Correction
Notice from the Centers for Medicare& Medicaid Services (CMS) making technical corrections to theNovember 13, 2023, final rule. This correcting document is effective January 31, 2024. (Source: Federal Register updates via the Rural Assistance Center)
Source: Federal Register updates via the Rural Assistance Center - January 31, 2024 Category: Rural Health Source Type: news
Takeda ’s Gammagard Liquid Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
New Indication Delivers on Takeda’s Commitment to Expanding its Broad and Diverse Immunoglobulin (IG) Portfolio to Meet the Needs of People Living with CIDP
Approval Supported by Phase 3 ADVANCE-CIDP Open-label Study Data Demonstrating... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 29, 2024 Category: Drugs & Pharmacology Source Type: news
U.S. FDA Approves Takeda ’s Hyqvia as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Hyqvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], the Only up to Once Monthly (every 2, 3 or 4 weeks) Subcutaneous Immunoglobulin (SCIG) Infusion to Treat CIDP, Can Be Administered by a Healthcare Professional or... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 16, 2024 Category: Drugs & Pharmacology Source Type: news
FDA Approves Alyglo (Immune Globulin Intravenous, Human-stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)
YOGIN, South Korea, Dec. 17, 2023 /PRNewswire/ -- GC Biopharma Corp (006280.KS) today announces that the US Food and Drug Administration (FDA) has approved Alyglo (immune globulin intravenous, human-stwk) 10% Liquid, formerly referred to... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 17, 2023 Category: Drugs & Pharmacology Source Type: news
CMS: Medicare Program; Calendar Year (CY) 2024 Home Health (HH) Prospective Payment System Rate Update; HH Quality Reporting Program Requirements; HH Value-Based Purchasing Expanded Model Requirements; Home Intravenous Immune Globulin Items and Services; Hospice Informal Dispute Resolution and Special Focus Program Requirements, Certain Requirements for Durable Medical Equipment Prosthetics and Orthotics Supplies; and Provider and Supplier Enrollment Requirements
Notice of final rule from the Centers for Medicare& Medicaid Services (CMS) updating the home health and home infusion therapy services payment rates for calendar year (CY) 2024. This rule also finalizes proposals to rebase and revise the home health market basket; revise the labor-related share; update the Home Health Quality Reporting Program (HH QRP) requirements; update the expanded Home Health Value-Based Purchasing (HHVBP) Model; and add an informal dispute resolution (IDR) and special focus program (SFP) for hospice, among other things. Also discusses comments received regarding access to home health aide services. ...
Source: Federal Register updates via the Rural Assistance Center - November 13, 2023 Category: Rural Health Source Type: news
With new flurry of clinical trials, NIH finally seeks treatments for Long Covid
The National Institutes of Health (NIH) yesterday announced
new clinical trials to test a diverse array of treatment strategies
—from an intravenous immune drug to light therapy and a dietary supplement—in people with Long Covid, the disabling syndrome that can follow infection with the pandemic coronavirus. The focus is on mitigating some of the most common and debilitating symptoms including brain fog and sleep troubles.
Most of the trials will include 100 to 300 people with Long Covid and will start to enroll this year, officials said. One, a multiweek study of the antiviral Paxlovid, has started to ...
Source: ScienceNOW - August 1, 2023 Category: Science Source Type: news
CMS: Medicare Program; Calendar Year (CY) 2024 Home Health (HH) Prospective Payment System Rate Update; HH Quality Reporting Program Requirements; HH Value-Based Purchasing Expanded Model Requirements; Home Intravenous Immune Globulin Items and Services; Hospice Informal Dispute Resolution and Special Focus Program Requirements, Certain Requirements for Durable Medical Equipment Prosthetics and Orthotics Supplies; and Provider and Supplier Enrollment Requirements
Notice of proposed rule from the Centers for Medicare and Medicaid Services (CMS) updating the home health payment rates for calendar year (CY) 2024. This rule also proposes rebasing and revising the home health market basket; revising the labor-related share proposes changes to the Home Health Quality Reporting Program (HH QRP) requirements; changing the expanded Home Health Value-Based Purchasing (HHVBP) Model; and adding an informal dispute resolution (IDR) and special focus program (SPF) for hospice, among other things. Also provides information on home health utilization trends and seeks comments regarding access to h...
Source: Federal Register updates via the Rural Assistance Center - July 10, 2023 Category: Rural Health Source Type: news
CSL Behring Receives FDA Approval for Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) 50mL Prefilled Syringe
KING OF PRUSSIA, Pa., April 18, 2023 /PRNewswire/ -- Global biotechnology leader CSL Behring today announced the U.S. Food and Drug Administration (FDA) approved a 50mL/10gm prefilled syringe for Hizentra® (Immune Globulin Subcutaneous [Human]... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 18, 2023 Category: Drugs & Pharmacology Source Type: news
IVIg Proves Effective for Dermatomyositis in Phase 3 Trial IVIg Proves Effective for Dermatomyositis in Phase 3 Trial
Prior to this trial, intravenous immune globulin had not been fully studied for the treatment of dermatomyositis.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - October 7, 2022 Category: Dermatology Tags: Rheumatology News Source Type: news
IV Immune Globulin Bests Placebo for Dermatomyositis
WEDNESDAY, Oct. 5, 2022 -- Significantly more adults with dermatomyositis receiving intravenous immune globulin (IVIG) versus placebo have a response of at least minimal improvement, according to a study published in the Oct. 6 issue of the New... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 5, 2022 Category: Pharmaceuticals Source Type: news
Cutaquig (Immune Globulin Intravenous, Human) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 30, 2022 Category: Drugs & Pharmacology Source Type: news
Panzyga (Immune Globulin Intravenous, human - Ifas Liquid Preparation) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 24, 2022 Category: Drugs & Pharmacology Source Type: news
Octagam (Immune Globulin Intravenous (Human) 5% Liquid Preparation) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 14, 2022 Category: Drugs & Pharmacology Source Type: news
Q & A: What you need to know about monkeypox
Monkeypox burst into the headlines this month after cases were diagnosed in Africa, Europe, North America and Australia.In an interview,Anne Rimoin, the Gordon-Levin Professor of Infectious Diseases and Public Health at the UCLA Fielding School of Public Health, offered insights about the disease, which she has studied for two decades. Rimoin has been director of theUCLA Center for Global and Immigrant Health and is the founder of the UCLA –DRC Health Research and Training Program in the Democratic Republic of the Congo.In simplest terms, what is monkeypox?Monkeypox is a viral zoonosis, a virus that is transmitted from a...
Source: UCLA Newsroom: Health Sciences - May 26, 2022 Category: Universities & Medical Training Source Type: news
Epidemiology of rabies immune globulin use in paediatric and adult patients in the USA: a cross-sectional prevalence study - Burke RV, Russo P, Sicilia M, Wolowich W, Amega N, Nguyen HB.
OBJECTIVES: To compare the epidemiology of paediatric and adult patients receiving rabies immune globulin (RIG). DESIGN: Cross-sectional prevalence study.
SETTING: Eligible participants from the Symphony Integrated Dataverse presenting between ... (Source: SafetyLit)
Source: SafetyLit - May 2, 2022 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
